Key Points
- Insider sale: David Malcom Rodman sold 14,058 shares on March 13 at an average price of $26.26 for $369,163.08, leaving him with 76,140 shares (about $1.999M) — a 15.59% reduction in his ownership.
- Rodman has been selling repeatedly since January (notable sales include 14,055 shares on Feb 13 and 11,367 shares on Jan 14), indicating ongoing insider selling activity over recent months.
- Market and analyst context: MLYS opened at $25.73 (down ~1.8%), with a 50-day/200-day moving average of $30.25/$35.73 and a $2.12B market cap; the company reported a Q loss of ($0.40) per share that beat estimates, and analysts have an average target of $49.14 with a majority rating the stock a Buy.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of the business's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $27.37, for a total transaction of $173,744.76. Following the completion of the sale, the insider owned 82,489 shares of the company's stock, valued at approximately $2,257,723.93. This represents a 7.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
David Malcom Rodman also recently made the following trade(s):
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total transaction of $58,269.64.
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total transaction of $11,505.03.
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total value of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total value of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total value of $65,585.91.
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total value of $13,353.60.
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total value of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.75, for a total value of $252,469.75.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total value of $205,167.36.
Mineralys Therapeutics Price Performance
MLYS opened at $25.73 on Tuesday. The business's 50-day moving average is $30.25 and its two-hundred day moving average is $35.73. Mineralys Therapeutics, Inc. has a 1 year low of $10.44 and a 1 year high of $47.65. The firm has a market capitalization of $2.12 billion, a PE ratio of -10.86 and a beta of 0.57.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Institutional Investors Weigh In On Mineralys Therapeutics
A number of large investors have recently bought and sold shares of MLYS. AQR Capital Management LLC acquired a new position in Mineralys Therapeutics in the 1st quarter worth approximately $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock valued at $271,000 after acquiring an additional 702 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company's stock worth $4,739,000 after acquiring an additional 186,480 shares during the period. Woodline Partners LP acquired a new stake in shares of Mineralys Therapeutics in the first quarter worth $757,000. Finally, Profund Advisors LLC purchased a new position in shares of Mineralys Therapeutics during the second quarter worth $164,000. Hedge funds and other institutional investors own 84.46% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on MLYS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. HC Wainwright set a $56.00 target price on Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Stifel Nicolaus upped their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Bank of America increased their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a "buy" rating in a research note on Friday. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a report on Friday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $49.14.
View Our Latest Report on MLYS
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
